Data on Solid Cancer Described by Researchers at Guangxi Medical University Cancer Hospital (A novel anti-CTLA-4 nanobody-IL12 fusion protein in combination with a dendritic cell/tumour fusion cell vaccine enhances the antitumour activity of...).

Researchers at Guangxi Medical University Cancer Hospital have developed a novel anti-CTLA-4 nanobody-IL12 fusion protein that, when combined with a dendritic cell/tumour fusion cell vaccine, enhances the antitumour activity of CD8+ T cells in solid tumors. The fusion protein was found to induce stronger and longer-lasting T-cell immune responses in vitro and in mice with xenografts. The study suggests the potential clinical application of this fusion approach for various nanobodies in cancer treatment. [Extracted from the article]